Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-10-03

FDA Approved: LAMIVUDINE — Supplemental Application (Apotex Corp.)

View source ↗

Summary

FDA approved a supplemental application for Apotex Corp.'s lamivudine, expanding access to a generic lamivudine product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lamivudine (lamivudine)

Snippet

SUPPL AP for LAMIVUDINE (LAMIVUDINE)